抗心律失常药物用于不可电击转可电击性院外心脏骤停:ALPS研究
本研究为ALPS试验的预设分析,纳入1063例初始不可电击心律、后转为难治性室颤/无脉性室速的院外心脏骤停患者,随机接受胺碘酮、利多卡因或安慰剂。主要结局出院生存率三组分别为4.1%、3.1%和1.9%(P=0.24),无统计学差异,但活性药物组点估计值较高且不良反应少。
要点
- 不可电击转可电击院外心脏骤停患者出院生存率低,但并非必然致命。
- 胺碘酮或利多卡因较安慰剂生存点估计值更高,但未达统计学显著性。
- 活性药物组所需电击次数、补充剂量及辅助抗心律失常药更少(P<0.05)。
核心结论
- 不可电击转可电击院外心脏骤停患者预后差但非必然致命;胺碘酮或利多卡因较安慰剂生存点估计值更高但无统计学显著性,且不增加不良反应或残疾风险。
研究设计与样本
- ALPS试验的预设分析,前瞻性随机双盲安慰剂对照,纳入1063例初始不可电击心律、后出现难治性室颤/无脉性室速的成人非创伤性院外心脏骤停患者,由急救人员给予胺碘酮、利多卡因或安慰剂。
主要发现
- 出院生存率:胺碘酮组16例(4.1%)、利多卡因组11例(3.1%)、安慰剂组6例(1.9%),P=0.24。
- 胺碘酮 vs 安慰剂校正绝对生存差异2.3%(95%CI -0.3~4.8),P=0.08;利多卡因 vs 安慰剂1.2%(95%CI -1.1~3.6),P=0.30。
- 活性药物组所需电击次数、补充剂量及辅助抗心律失常药物均少于安慰剂组(P<0.05)。
- 超过50%的生存者功能独立或仅需少量帮助;药物相关不良反应少见。
- 治疗分配与初始心律(无收缩、无脉性电活动或室颤/室速)对出院生存无显著交互作用。
临床怎么用
- 对于初始不可电击心律后转为难治性室颤/无脉性室速的院外心脏骤停患者,可考虑使用胺碘酮或利多卡因,但需知晓生存获益未达统计学显著性。
- 使用胺碘酮或利多卡因可能减少电击次数及辅助抗心律失常药物需求,且不增加不良反应或残疾风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Out-of-hospital cardiac arrest (OHCA) commonly presents with nonshockable rhythms (asystole and pulseless electric activity). It is unknown whether antiarrhythmic drugs are safe and effective when nonshockable rhythms evolve to shockable rhythms (ventricular fibrillation/pulseless ventricular tachycardia [VF/VT]) during resuscitation. METHODS: Adults with nontraumatic OHCA, vascular access, and VF/VT anytime after ≥1 shock(s) were prospectively randomized, double-blind, to receive amiodarone, lidocaine, or placebo by paramedics. Patients presenting with initial shock-refractory VF/VT were previously reported. The current study was a prespecified analysis in a separate cohort that initially presented with nonshockable OHCA and was randomized on subsequently developing shock-refractory VF/VT. The primary outcome was survival to hospital discharge. Secondary outcomes included discharge functional status and adverse drug-related effects. RESULTS: Of 37 889 patients with OHCA, 3026 with initial VF/VT and 1063 with initial nonshockable-turned-shockable rhythms were treatment-eligible, were randomized, and received their assigned drug. Baseline characteristics among patients with nonshockable-turned-shockable rhythms were balanced across treatment arms, except that recipients of a placebo included fewer men and were less likely to receive bystander cardiopulmonary resuscitation. Active-drug recipients in this cohort required fewer shocks, supplemental doses of their assigned drug, and ancillary antiarrhythmic drugs than recipients of a placebo (P<0.05). In all, 16 (4.1%) amiodarone, 11 (3.1%) lidocaine, and 6 (1.9%) placebo-treated patients survived to hospital discharge (P=0.24). No significant interaction between treatment assignment and discharge survival occurred with the initiating OHCA rhythm (asystole, pulseless electric activity, or VF/VT). Survival in each of these categories was consistently higher with active drugs, although the trends were not statistically significant. Adjusted absolute differences (95% confidence interval) in survival from nonshockable-turned-shockable arrhythmias with amiodarone versus placebo were 2.3% (-0.3, 4.8), P=0.08, and for lidocaine versus placebo 1.2% (-1.1, 3.6), P=0.30. More than 50% of these survivors were functionally independent or required minimal assistance. Drug-related adverse effects were infrequent. CONCLUSIONS: Outcome from nonshockable-turned-shockable OHCA is poor but not invariably fatal. Although not statistically significant, point estimates for survival were greater after amiodarone or lidocaine than placebo, without increased risk of adverse effects or disability and consistent with previously observed favorable trends from treatment of initial shock-refractory VF/VT with these drugs. Together the findings may signal a clinical benefit that invites further investigation. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01401647.
引用
- Kudenchuk PJ, Leroux BG, Daya M, et al. Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo). Circulation. 2017. PMID: 28904070. doi:10.1161/CIRCULATIONAHA.117.028624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。